EMA Authorised: Ninlaro (ixazomib citrate) — Takeda Pharma A/S

View source ↗

Summary

EMA authorised Ninlaro (ixazomib citrate) for the treatment of multiple myeloma. The product has orphan medicine designation and Takeda Pharma A/S is the market…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• NINLARO (ixazomib)

Snippet

Status: Authorised. Therapeutic area: Multiple Myeloma. MAH: Takeda Pharma A/S. Decision date: 16/08/2024. Orphan medicine